Table 4.
Tetravalent dengue vaccine (TDV) virus viremia expressed in terms of the number and proportion of participants with virus detected by RT-PCR on day 7, 14, or 21 after dengue vaccination or quantified by plaque assay
| VDV1-primed (N = 7) | VDV2-primed (N = 8) | All VDV-primed (N = 15) | YF-primed (N = 8) | Naive (N = 12) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| RT-PCR | ||||||||||
| Any serotype non-serotype–specific TDV viremia | 3 | 43 | 4 | 50 | 7 | 47 | 7 | 88 | 10 | 83 |
| Serotype 1 | 0 | 0 | 0 | 0 | 0 | |||||
| Serotype 2 | 0 | 0 | 0 | 0 | 0 | |||||
| Serotype 3 | 0 | 1 | 13 | 1 | 7 | 3 | 38 | 2 | 17 | |
| Serotype 4 | 1 | 14 | 2 | 25 | 3 | 20 | 5 | 63 | 6 | 50 |
| Plaque assay | ||||||||||
| Serotype 1 | 0 | 0 | 0 | 0 | 0 | |||||
| Serotype 2 | 0 | 0 | 0 | 0 | 0 | |||||
| Serotype 3 | 0 | 0 | 0 | 0 | 0 | |||||
| Serotype 4 | 0 | 0 | 2 | 25 | 1 | 8 | ||||